

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

Tevagrastim 30 MIU/0.5 mL solution for injection/infusion

Tevagrastim 48 MIU/0.8 mL solution for injection/infusion

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each mL of solution for injection/infusion contains 60 million international units [MIU] (600 µg) of filgrastim.

Tevagrastim 30 MIU/0.5 mL solution for injection/infusion

Each pre-filled syringe contains 30 MIU (300 µg) of filgrastim in 0.5 mL solution for injection/infusion.

Tevagrastim 48 MIU/0.8 mL solution for injection/infusion

Each pre-filled syringe contains 48 MIU (480 µg) of filgrastim in 0.8 mL solution for injection/infusion.

Filgrastim (recombinant methionyl human granulocyte colony-stimulating factor) is produced in *Escherichia coli* K802 by recombinant DNA technology.

Excipient with known effect

Each mL of solution contains 50 mg of sorbitol.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Solution for injection/infusion

Clear, colourless solution.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Tevagrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.

The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.

Tevagrastim is indicated for the mobilisation of peripheral blood progenitor cells (PBPC).

In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of $\leq 0.5 \times 10^9/\text{L}$, and a history of severe or recurrent infections, long term administration of Tevagrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.

Tevagrastim is indicated for the treatment of persistent neutropenia (ANC less than or equal to $1.0 \times 10^9/\text{L}$) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.

4.2 Posology and method of administration

Filgrastim therapy should only be given in collaboration with an oncology centre which has experience in granulocyte colony-stimulating factor (G-CSF) treatment and haematology and has the necessary diagnostic facilities. The mobilisation and apheresis procedures should be performed in collaboration with an oncology-haematology centre with acceptable experience in this field and where the monitoring of haematopoietic progenitor cells can be correctly performed.

Established cytotoxic chemotherapy

Posology

The recommended dose of filgrastim is 0.5 MIU (5 µg)/kg/day. The first dose of filgrastim should be administered at least 24 hours after cytotoxic chemotherapy. In randomised clinical trials, a subcutaneous dose of 23 MIU (230 µg)/m²/day (4.0 to 8.4 µg/kg/day) was used.

Daily dosing with filgrastim should continue until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range. Following established chemotherapy for solid tumours, lymphomas and lymphoid leukaemias, it is expected that the duration of treatment required to fulfil these criteria will be up to 14 days. Following induction and consolidation treatment for acute myeloid leukaemia the duration of treatment may be substantially longer (up to 38 days) depending on the type, dose and schedule of cytotoxic chemotherapy used.

In patients receiving cytotoxic chemotherapy, a transient increase in neutrophil counts is typically seen 1 to 2 days after initiation of filgrastim therapy. However, for a sustained therapeutic response, filgrastim therapy should not be discontinued before the expected nadir has passed and the neutrophil count has recovered to the normal range. Premature discontinuation of filgrastim therapy prior to the time of the expected neutrophil nadir is not recommended.

Method of administration

Filgrastim may be given as a daily subcutaneous injection or as a daily intravenous infusion diluted in 5% glucose solution for infusion given over 30 minutes (see section 6.6). The subcutaneous route is preferred in most cases. There is some evidence from a study of single dose administration that intravenous dosing may shorten the duration of effect. The clinical relevance of this finding to multiple dose administration is not clear. The choice of route should depend on the individual clinical circumstance.

In patients treated with myeloablative therapy followed by bone marrow transplantation

Posology

The recommended starting dose of filgrastim is 1.0 MIU (10 µg)/kg/day.

The first dose of filgrastim should be administered at least 24 hours after cytotoxic chemotherapy and at least 24 hours after bone marrow infusion.

Once the neutrophil nadir has been passed the daily dose of filgrastim should be titrated against the neutrophil response as follows:

Neutrophil count	Filgrastim dose adjustment
> 1.0 x 10 ⁹ /L for 3 consecutive days	Reduce to 0.5 MIU (5 µg)/kg/day
Then, if ANC remains > 1.0 x 10 ⁹ /L for 3 more consecutive days	Discontinue filgrastim
If the ANC decreases to < 1.0 x 10 ⁹ /L during the treatment period the dose of filgrastim should be re-escalated according to the above steps	

ANC = absolute neutrophil count

Method of administration

Filgrastim may be given as a 30 minute or 24 hour intravenous infusion or given by continuous 24 hour subcutaneous infusion. Filgrastim should be diluted in 20 mL of 5% glucose solution for infusion (see section 6.6).

For the mobilisation of PBPCs in patients undergoing myelosuppressive or myeloablative therapy followed by autologous PBPC transplantation

Posology

The recommended dose of filgrastim for PBPC mobilisation when used alone is 1.0 MIU (10 µg)/kg/day for 5 to 7 consecutive days. Timing of leukapheresis: 1 or 2 leukapheresis on days 5 and 6 are often sufficient. In other circumstances, additional leukapheresis may be necessary. Filgrastim dosing should be maintained until the last leukapheresis.

The recommended dose of filgrastim for PBPC mobilisation after myelosuppressive chemotherapy is 0.5 MIU (5 µg)/kg/day from the first day after completion of chemotherapy until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range. Leukapheresis should be performed during the period when the ANC rises from < 0.5 x 10⁹/L to > 5.0 x 10⁹/L. For patients who have not had extensive chemotherapy, one leukapheresis is often sufficient. In other circumstances, additional leukapheresis are recommended.

Method of administration

Filgrastim for PBPC mobilisation when used alone:

Filgrastim may be given as a 24 hour subcutaneous continuous infusion or subcutaneous injection. For infusions, filgrastim should be diluted in 20 mL of 5% glucose solution for infusion (see section 6.6).

Filgrastim for PBPC mobilisation after myelosuppressive chemotherapy:

Filgrastim should be given by subcutaneous injection.

For the mobilisation of PBPCs in normal donors prior to allogeneic PBPC transplantation

Posology

For PBPC mobilisation in normal donors, filgrastim should be administered at 1.0 MIU (10 µg)/kg/day for 4 to 5 consecutive days. Leukapheresis should be started at day 5 and continued until day 6 if needed in order to collect 4 x 10⁶ CD34⁺ cells/kg recipient bodyweight.

Method of administration

Filgrastim should be given by subcutaneous injection.

In patients with severe chronic neutropenia (SCN)

Posology

Congenital neutropenia

The recommended starting dose is 1.2 MIU (12 µg)/kg/day as a single dose or in divided doses.

Idiopathic or cyclic neutropenia

The recommended starting dose is 0.5 MIU (5 µg)/kg/day as a single dose or in divided doses.

Dose adjustment

Filgrastim should be administered daily by subcutaneous injection until the neutrophil count has reached and can be maintained at more than $1.5 \times 10^9/L$. When the response has been obtained, the minimal effective dose to maintain this level should be established. Long-term daily administration is required to maintain an adequate neutrophil count. After one to two weeks of therapy, the initial dose may be doubled or halved depending upon the patient's response. Subsequently the dose may be individually adjusted every 1 to 2 weeks to maintain the average neutrophil count between $1.5 \times 10^9/L$ and $10 \times 10^9/L$. A faster schedule of dose escalation may be considered in patients presenting with severe infections. In clinical trials, 97 % of patients who responded had a complete response at doses of ≤ 2.4 MIU (24 µg)/kg/day. The long-term safety of filgrastim administration above 2.4 MIU (24 µg)/kg/day in patients with SCN has not been established.

Method of administration

Congenital, idiopathic or cyclic neutropenia:

Filgrastim should be given by subcutaneous injection.

In patients with HIV infection

Posology

For reversal of neutropenia

The recommended starting dose of filgrastim is 0.1 MIU (1 µg)/kg/day with titration up to a maximum of 0.4 MIU (4 µg)/kg/day until a normal neutrophil count is reached and can be maintained (ANC $> 2.0 \times 10^9/L$). In clinical studies, > 90 % of patients responded at these doses, achieving reversal of neutropenia in a median of 2 days.

In a small number of patients (< 10 %), doses up to 1.0 MIU (10 µg)/kg/day were required to achieve reversal of neutropenia.

For maintaining normal neutrophil counts

When reversal of neutropenia has been achieved, the minimal effective dose to maintain a normal neutrophil count should be established. Initial dose adjustment to alternate day dosing with 30 MIU (300 µg)/day is recommended. Further dose adjustment may be necessary, as determined by the patient's ANC, to maintain the neutrophil count at $> 2.0 \times 10^9/L$. In clinical studies, dosing with 30 MIU (300 µg)/day on 1 to 7 days per week was required to maintain the ANC $> 2.0 \times 10^9/L$, with the median dose frequency being 3 days per week. Long-term administration may be required to maintain the ANC $> 2.0 \times 10^9/L$.

Method of administration

Reversal of neutropenia or maintaining normal neutrophil counts: Filgrastim should be given by subcutaneous injection.

Special populations

Elderly

Clinical trials with filgrastim have included a small number of elderly patients but special studies have not been performed in this group and therefore specific dosage recommendations cannot be made.

Patients with renal or hepatic impairment

Studies of filgrastim in patients with severe impairment of renal or hepatic function demonstrate that it exhibits a similar pharmacokinetic and pharmacodynamic profile to that seen in normal individuals. Dose adjustment is not required in these circumstances.

Paediatric use in the SCN and cancer settings

Sixty-five percent of the patients studied in the SCN trial programme were under 18 years of age. The efficacy of treatment was clear for this age group, which included most patients with congenital neutropenia. There were no differences in the safety profiles for paediatric patients treated for SCN.

Data from clinical studies in paediatric patients indicate that the safety and efficacy of filgrastim are similar in both adults and children receiving cytotoxic chemotherapy.

The dosage recommendations in paediatric patients are the same as those in adults receiving myelosuppressive cytotoxic chemotherapy.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Special warnings and precautions across indications

Hypersensitivity

Hypersensitivity, including anaphylactic reactions, occurring on initial or subsequent treatment have been reported in patients treated with filgrastim. Permanently discontinue Tevagrastim in patients with clinically significant hypersensitivity. Do not administer filgrastim to patients with a history of hypersensitivity to filgrastim or pegfilgrastim.

Pulmonary adverse effects

Pulmonary adverse reactions, in particular interstitial lung disease, have been reported after G-CSF administration. Patients with a recent history of lung infiltrates or pneumonia may be at higher risk. The onset of pulmonary signs such as cough, fever and dyspnoea in association with radiological signs of pulmonary infiltrates and deterioration in pulmonary function may be preliminary signs of acute respiratory distress syndrome (ARDS). Filgrastim should be discontinued and appropriate treatment given.

Glomerulonephritis

Glomerulonephritis has been reported in patients receiving filgrastim and pegfilgrastim. Generally, events of glomerulonephritis resolved after dose reduction or withdrawal of filgrastim and pegfilgrastim. Urinalysis monitoring is recommended.

Capillary leak syndrome

Capillary leak syndrome which can be life threatening if treatment is delayed, has been reported after G-CSF administration and is characterised by hypotension, hypoalbuminaemia, oedema and haemoconcentration. Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care (see section 4.8).

Splenomegaly and splenic rupture

Generally asymptomatic cases of splenomegaly and cases of splenic rupture have been reported in patients and normal donors following administration of filgrastim. Some cases of splenic rupture were

fatal. Therefore, spleen size should be carefully monitored (e.g. clinical examination, ultrasound). A diagnosis of splenic rupture should be considered in donors and/or patients reporting left upper abdominal or shoulder tip pain. Dose reductions of filgrastim have been noted to slow or stop the progression of splenic enlargement in patients with severe chronic neutropenia, and in 3% of patients a splenectomy was required.

Malignant cell growth

Granulocyte colony-stimulating factor can promote growth of myeloid cells *in vitro* and similar effects may also be seen on some non-myeloid cells *in vitro*.

Myelodysplastic syndrome or chronic myeloid leukemia

The safety and efficacy of filgrastim administration in patients with myelodysplastic syndrome or chronic myelogenous leukaemia have not been established. Filgrastim is not indicated for use in these conditions. Particular care should be taken to distinguish the diagnosis of blast transformation of chronic myeloid leukaemia from acute myeloid leukaemia.

Acute myeloid leukaemia

In view of limited safety and efficacy data in patients with secondary AML, filgrastim should be administered with caution. The safety and efficacy of filgrastim administration in de novo AML patients aged < 55 years with good cytogenetics (t(8;21), t(15;17), and inv(16)) have not been established.

Thrombocytopenia

Thrombocytopenia has been reported in patients receiving filgrastim. Platelet counts should be monitored closely, especially during the first few weeks of filgrastim therapy. Consideration should be given to temporary discontinuation or dose reduction of filgrastim in patients with severe chronic neutropenia who develop thrombocytopenia (platelet count < 100 x 10⁹/l).

Leukocytosis

White blood cell counts of 100 x 10⁹/L or greater have been observed in less than 5 % of cancer patients receiving filgrastim at doses above 0.3 MIU/kg/day (3 µg/kg/day). No undesirable effects directly attributable to this degree of leukocytosis have been reported. However, in view of the potential risks associated with severe leukocytosis, a white blood cell count should be performed at regular intervals during filgrastim therapy. If leukocyte counts exceed 50 x 10⁹/L after the expected nadir, filgrastim should be discontinued immediately. However, during the period of administration of filgrastim for PBPC mobilisation, filgrastim should be discontinued or its dosage should be reduced if the leukocyte counts rise to > 70 x 10⁹/L.

Immunogenicity

As with all therapeutic proteins, there is a potential for immunogenicity. Rates of generation of antibodies against filgrastim is generally low. Binding antibodies do occur as expected with all biologics; however, they have not been associated with neutralising activity at present.

Aortitis

Aortitis has been reported after G-CSF administration in healthy subjects and in cancer patients. The symptoms experienced included fever, abdominal pain, malaise, back pain and increased inflammatory markers (e.g. C-reactive protein and white blood cell count). In most cases aortitis was diagnosed by CT scan and generally resolved after withdrawal of G-CSF. See also section 4.8.

Special warnings and precautions associated with co-morbidities

Special precautions in sickle cell trait and sickle cell disease

Sickle cell crisis, in some cases fatal, have been reported with the use of filgrastim in patients with sickle cell trait or sickle cell disease. Physicians should use caution when prescribing filgrastim in patients with sickle cell trait or sickle cell disease.

Osteoporosis

Monitoring of bone density may be indicated in patients with underlying osteoporotic bone diseases who undergo continuous therapy with filgrastim for more than 6 months.

Special precautions in cancer patients

Filgrastim should not be used to increase the dose of cytotoxic chemotherapy beyond established dosage regimens.

Risks associated with increased doses of chemotherapy

Special caution should be used when treating patients with high-dose chemotherapy because improved tumour outcome has not been demonstrated and intensified doses of chemotherapeutic agents may lead to increased toxicities including cardiac, pulmonary, neurologic and dermatologic effects (please refer to the Summary of Product Characteristics of the specific chemotherapy agents used).

Effect of chemotherapy on erythrocytes and thrombocytes

Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive chemotherapy. Because of the potential of receiving higher doses of chemotherapy (e.g. full doses on the prescribed schedule) the patient may be at greater risk of thrombocytopenia and anaemia. Regular monitoring of platelet count and haematocrit is recommended. Special care should be taken when administering single or combination chemotherapeutic agents which are known to cause severe thrombocytopenia.

The use of filgrastim mobilised PBPCs has been shown to reduce the depth and duration of thrombocytopenia following myelosuppressive or myeloablative chemotherapy.

Myelodysplastic syndrome and acute myeloid leukaemia in breast and lung cancer patients

In the post-marketing observational study setting, myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) have been associated with the use of pegfilgrastim, an alternative G-CSF medicine, in conjunction with chemotherapy and/or radiotherapy in breast and lung cancer patients. A similar association between filgrastim and MDS/AML has not been observed. Nonetheless, patients with breast cancer and patients with lung cancer should be monitored for signs and symptoms of MDS/AML.

Other special precautions

The effects of filgrastim in patients with substantially reduced myeloid progenitors have not been studied. Filgrastim acts primarily on neutrophil precursors to exert its effect in elevating neutrophil counts. Therefore, in patients with reduced precursors neutrophil response may be diminished (such as those treated with extensive radiotherapy or chemotherapy, or those with bone marrow infiltration by tumour).

Vascular disorders, including veno-occlusive disease and fluid volume disturbances, have been reported occasionally in patients undergoing high-dose chemotherapy followed by transplantation.

There have been reports of graft versus host disease (GvHD) and fatalities in patients receiving G-CSF after allogeneic bone marrow transplantation (see sections 4.8 and 5.1).

Increased haematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient abnormal bone scans. This should be considered when interpreting bone-imaging results.

Special precautions in patients undergoing PBPC mobilisation

Mobilisation

There are no prospectively randomised comparisons of the two recommended mobilisation methods (filgrastim alone or in combination with myelosuppressive chemotherapy) within the same patient population. The degree of variation between individual patients and between laboratory assays of CD34⁺ cells mean that direct comparison between different studies is difficult. It is therefore difficult to recommend an optimum method. The choice of mobilisation method should be considered in relation to the overall objectives of treatment for an individual patient.

Prior exposure to cytotoxic agents

Patients who have undergone very extensive prior myelosuppressive therapy may not show sufficient mobilisation of PBPC to achieve the recommended minimum yield ($\geq 2.0 \times 10^6$ CD34⁺ cells/kg) or acceleration of platelet recovery to the same degree.

Some cytotoxic agents exhibit particular toxicities to the haematopoietic progenitor pool and may adversely affect progenitor mobilisation. Agents such as melphalan, carmustine (BCNU) and carboplatin, when administered over prolonged periods prior to attempts at progenitor mobilisation, may reduce progenitor yield. However, the administration of melphalan, carboplatin or BCNU together with filgrastim has been shown to be effective for progenitor mobilisation. When a PBPC transplantation is envisaged it is advisable to plan the stem cell mobilisation procedure early in the treatment course of the patient. Particular attention should be paid to the number of progenitors mobilised in such patients before the administration of high-dose chemotherapy. If yields are inadequate, as measured by the criteria above, alternative forms of treatment not requiring progenitor support should be considered.

Assessment of progenitor cell yields

In assessing the number of progenitor cells harvested in patients treated with filgrastim, particular attention should be paid to the method of quantitation. The results of flow cytometric analysis of CD34⁺ cell numbers vary depending on the precise methodology used and recommendations of numbers based on studies in other laboratories need to be interpreted with caution.

Statistical analysis of the relationship between the number of CD34⁺ cells re-infused and the rate of platelet recovery after high-dose chemotherapy indicates a complex but continuous relationship.

The recommendation of a minimum yield of $\geq 2.0 \times 10^6$ CD34⁺ cells/kg is based on published experience resulting in adequate haematologic reconstitution. Yields in excess of this appear to correlate with more rapid recovery, those below with slower recovery.

Special precautions in normal donors undergoing PBPC mobilisation

Mobilisation of PBPC does not provide a direct clinical benefit to normal donors and should only be considered for the purposes of allogeneic stem cell transplantation.

PBPC mobilisation should be considered only in donors who meet normal clinical and laboratory eligibility criteria for stem cell donation with special attention to haematological values and infectious disease.

The safety and efficacy of filgrastim have not been assessed in normal donors < 16 years or > 60 years.

Transient thrombocytopenia (platelets $< 100 \times 10^9/L$) following filgrastim administration and leukapheresis was observed in 35 % of subjects studied. Among these, two cases of platelets $< 50 \times 10^9/L$ were reported and attributed to the leukapheresis procedure.

If more than one leukapheresis is required, particular attention should be paid to donors with platelets $< 100 \times 10^9/L$ prior to leukapheresis; in general apheresis should not be performed if platelets $< 75 \times 10^9/L$.

Leukapheresis should not be performed in donors who are anticoagulated or who have known defects in haemostasis.

Donors who receive G-CSFs for PBPC mobilisation should be monitored until haematological indices return to normal.

Special precautions in recipients of allogeneic PBPCs mobilised with filgrastim

Current data indicate that immunological interactions between the allogeneic PBPC graft and the recipient may be associated with an increased risk of acute and chronic GvHD when compared with bone marrow transplantation.

Special precautions in SCN patients

Filgrastim should not be administered to patients with severe congenital neutropenia who develop leukaemia or have evidence of leukaemic evolution.

Blood cell counts

Other blood cell changes occur, including anaemia and transient increases in myeloid progenitors, which require close monitoring of cell counts

Transformation to leukaemia or myelodysplastic syndrome

Special care should be taken in the diagnosis of SCNs to distinguish them from other haematopoietic disorders such as aplastic anaemia, myelodysplasia and myeloid leukaemia. Complete blood cell counts with differential and platelet counts and an evaluation of bone marrow morphology and karyotype should be performed prior to treatment.

There was a low frequency (approximately 3 %) of myelodysplastic syndromes (MDS) or leukaemia in clinical trial patients with SCN treated with filgrastim. This observation has only been made in patients with congenital neutropenia. MDS and leukaemias are natural complications of the disease and are of uncertain relation to filgrastim therapy. A subset of approximately 12 % of patients who had normal cytogenetic evaluations at baseline was subsequently found to have abnormalities, including monosomy 7, on routine repeat evaluation. It is currently unclear whether long-term treatment of patients with SCN will predispose patients to cytogenetic abnormalities, MDS or leukaemic transformation. It is recommended to perform morphologic and cytogenetic bone marrow examinations in patients at regular intervals (approximately every 12 months).

Other special precautions

Causes of transient neutropenia such as viral infections should be excluded.

Haematuria was common and proteinuria occurred in a small number of patients. Regular urinalysis should be performed to monitor these events.

The safety and efficacy in neonates and patients with autoimmune neutropenia have not been established.

Special precautions in patients with HIV infection

Blood cell counts

ANC should be monitored closely, especially during the first few weeks of filgrastim therapy. Some patients may respond very rapidly and with a considerable increase in neutrophil count to the initial dose of filgrastim. It is recommended that the ANC is measured daily for the first 2 to 3 days of filgrastim administration. Thereafter, it is recommended that the ANC is measured at least twice weekly for the first two weeks and subsequently once per week or once every other week during maintenance therapy. During intermittent dosing with 30 MIU (300 µg)/day of filgrastim, there can be wide fluctuations in the patient's ANC over time. In order to determine a patient's trough or nadir ANC, it is recommended that blood samples are taken for ANC measurement immediately prior to any scheduled dosing with filgrastim.

Risk associated with increased doses of myelosuppressive medicinal products

Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive medicinal products. As a result of the potential to receive higher doses or a greater number of these medicinal products with filgrastim therapy, the patient may be at higher risk of developing thrombocytopenia and anaemia. Regular monitoring of blood counts is recommended (see above).

Infections and malignancies causing myelosuppression

Neutropenia may be due to bone marrow infiltrating opportunistic infections such as *Mycobacterium avium* complex or malignancies such as lymphoma. In patients with known bone marrow-infiltrating infections or malignancy, consider appropriate therapy for treatment of the underlying condition in addition to administration of filgrastim for treatment of neutropenia. The effects of filgrastim on neutropenia due to bone marrow-infiltrating infection or malignancy have not been well established.

All patients

Sorbitol

Tevagrastim contains sorbitol (E420). The additive effect of concomitantly given products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken into account.

For intravenous administration

Patients with hereditary fructose intolerance (HFI) must not be given this medicinal product unless strictly necessary. Infants and young children (below 2 years of age) may not yet be diagnosed with HFI. Medicinal products (containing sorbitol/fructose) given intravenously may be life-threatening and should not be given in this population unless there is an overwhelming clinical need and no alternatives are available.

A detailed history of HFI symptoms has to be taken of each patient before giving this medicinal product.

Sodium

This medicinal product contains less than 1 mmol sodium (23 mg) per pre-filled syringe, i.e. essentially 'sodium-free'.

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

4.5 Interaction with other medicinal products and other forms of interaction

The safety and efficacy of filgrastim given on the same day as myelosuppressive cytotoxic chemotherapy have not been definitively established. In view of the sensitivity of rapidly dividing myeloid cells to myelosuppressive cytotoxic chemotherapy, the use of filgrastim is not recommended in the period from 24 hours before to 24 hours after chemotherapy. Preliminary evidence from a small number of patients treated concomitantly with filgrastim and 5-Fluorouracil indicates that the severity of neutropenia may be exacerbated.

Possible interactions with other haematopoietic growth factors and cytokines have not yet been investigated in clinical trials.

Since lithium promotes the release of neutrophils, it is likely to potentiate the effect of filgrastim. Although this interaction has not been formally investigated, there is no evidence that such an interaction is harmful.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no or limited amount of data from the use of filgrastim in pregnant women. Studies in animals have shown reproductive toxicity. An increased incidence of embryo-loss has been observed in rabbits at high multiples of the clinical exposure and in the presence of maternal toxicity (see section 5.3). There are reports in the literature where the transplacental passage of filgrastim in pregnant women has been demonstrated.

Filgrastim is not recommended during pregnancy.

Breast-feeding

It is unknown whether filgrastim/metabolites are excreted in human milk. A risk to the breastfed newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from filgrastim therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

Fertility

Filgrastim did not affect reproductive performance or fertility in male or female rats (see section 5.3).

4.7 Effects on ability to drive and use machines

Filgrastim may have a minor influence on the ability to drive and use machines. Dizziness may occur following the administration of filgrastim (see section 4.8).

4.8 Undesirable effects

a. Summary of the safety profile

The most serious adverse reactions that may occur during filgrastim treatment include: anaphylactic reaction, serious pulmonary adverse events (including interstitial pneumonia and ARDS), capillary leak syndrome, severe splenomegaly/splenic rupture, transformation to myelodysplastic syndrome or leukaemia in SCN patients, GvHD in patients receiving allogeneic bone marrow transfer or peripheral blood cell progenitor cell transplant and sickle cell crisis in patients with sickle cell disease.

The most commonly reported adverse reactions are pyrexia, musculoskeletal pain (which includes bone pain, back pain, arthralgia, myalgia, pain in extremity, musculoskeletal pain, musculoskeletal chest pain, neck pain), anaemia, vomiting, and nausea. In clinical trials in cancer patients musculoskeletal pain was mild or moderate in 10%, and severe in 3% of patients.

b. Tabulated summary of adverse reactions

The data in the table below describe adverse reactions reported from clinical trials and spontaneous reporting. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

MedDRA system organ class	Adverse reactions			
	Very common (≥ 1/10)	Common (≥ 1/100 to < 1/10)	Uncommon (≥ 1/1,000 to < 1/100)	Rare (≥ 1/10,000 to < 1/1,000)
Infections and Infestations		Sepsis Bronchitis Upper respiratory tract infection Urinary tract infection		
Blood and lymphatic system disorders	Thrombocytopenia Anaemia ^e	Splenomegaly ^a Haemoglobin decreased ^e	Leukocytosis ^a	Splenic rupture ^a Sickle cell anaemia with crisis
Immune system disorders			Hypersensitivity Drug hypersensitivity ^a Graft versus Host Disease ^b	Anaphylactic reaction
Metabolis m and nutrition disorders		Decreased appetite ^e Blood lactate dehydrogenase increased	Hyperuricaemia Blood uric acid increased	Blood glucose decreased Pseudogout ^a (Chondrocalcinosis Pyrophosphate) Fluid volume disturbances
Psychiatric diorders		Insomnia		
Nervous system disorders	Headache ^a	Dizziness Hypoaesthesia Paraesthesia		
Vascular disorders		Hypertension Hypotension	Veno-occlusive disease ^d	Capillary leak syndrome ^a Aortitis
Respirator y, thoracic and mediastinal disorders		Haemoptysis Dyspnoea Cough ^a Oropharyngeal pain ^{a,e} Epistaxis	Acute respiratory distress syndrome ^a Respiratory failure ^a Pulmonary oedema ^a Pulmonary haemorrhage Interstitial lung disease ^a Lung infiltration ^a Hypoxia	
Gastro- intestinal disorders	Diarrhoea ^{a, e} Vomiting ^{a,e} Nausea ^a	Oral pain Constipation ^e		
Hepato- biliary disorders		Hepatomegaly Blood alkaline phosphatase increased	Aspartate aminotransferase increased Gamma-glutamyl transferase increased	

Skin and sub-cutaneous tissue disorders	Alopecia ^a	Rash ^a Erythema	Rash maculopapular	Cutaneous vasculitis ^a Sweets syndrome (acute febrile neutrophilic dermatosis)
Musculo-skeletal and connective tissue disorders	Musculoskeletal pain ^c	Muscle spasms	Osteoporosis	Bone density decreased Exacerbation of rheumatoid arthritis
Renal and urinary disorders		Dysuria Haematuria	Proteinuria	Glomerulonephritis Urine abnormality
General disorders and administration site conditions	Fatigue ^a Mucosal inflammation ^a Pyrexia	Chest pain ^a Pain ^a Asthenia ^a Malaise ^c Oedema peripheral ^c	Injection site reaction	
Injury, poisoning and procedural complications		Transfusion reaction ^c		

^a See section c (Description of selected adverse reactions)

^b There have been reports of GvHD and fatalities in patients after allogeneic bone marrow transplantation (see section c)

^c Includes bone pain, back pain, arthralgia, myalgia, pain in extremity, musculoskeletal pain, musculoskeletal chest pain, neck pain

^d Cases were observed in the post-marketing setting in patients undergoing bone marrow transplant or PBPC mobilisation

^e Adverse events with higher incidence in filgrastim patients compared to placebo and associated with the sequelae of the underlying malignancy or cytotoxic chemotherapy

c. Description of selected adverse reactions

Hypersensitivity

Hypersensitivity-type reactions including anaphylaxis, rash, urticaria, angioedema, dyspnoea and hypotension occurring on initial or subsequent treatment have been reported in clinical studies and in post-marketing experience. Overall, reports were more common after IV administration. In some cases, symptoms have recurred with rechallenge, suggesting a causal relationship. Tevagrastim should be permanently discontinued in patients who experience a serious allergic reaction.

Pulmonary adverse events

In clinical studies and the post-marketing setting pulmonary adverse effects including interstitial lung disease, pulmonary oedema, and lung infiltration have been reported in some cases with an outcome of respiratory failure or acute respiratory distress syndrome (ARDS), which may be fatal (see section 4.4).

Splenomegaly and splenic rupture

Cases of splenomegaly and splenic rupture have been reported following administration of filgrastim.

Some cases of splenic rupture were fatal (see section 4.4).

Capillary leak syndrome

Cases of capillary leak syndrome have been reported with granulocyte colony-stimulating factor use. These have generally occurred in patients with advanced malignant diseases, sepsis, taking multiple chemotherapy medications or undergoing apheresis (see section 4.4).

Cutaneous vasculitis

Cutaneous vasculitis has been reported in patients treated with filgrastim. The mechanism of vasculitis in patients receiving filgrastim is unknown. During long term use cutaneous vasculitis has been reported in 2% of SCN patients.

Leukocytosis

Leukocytosis ($\text{WBC} > 50 \times 10^9/\text{l}$) was observed in 41% of normal donors and transient thrombocytopenia (platelets $< 100 \times 10^9/\text{l}$) following filgrastim and leukapheresis was observed in 35% of donors (see section 4.4).

Sweets syndrome

Cases of Sweets syndrome (acute febrile neutrophilic dermatosis) have been reported in patients treated with filgrastim.

Pseudogout (chondrocalcinosis pyrophosphate)

Pseudogout (chondrocalcinosis pyrophosphate) has been reported in patients with cancer treated with filgrastim.

GvHD

There have been reports of GvHD and fatalities in patients receiving G-CSF after allogeneic bone marrow transplantation (see sections 4.4 and 5.1).

d. Paediatric population

Data from clinical studies in paediatric patients indicate that the safety and efficacy of filgrastim are similar in both adults and children receiving cytotoxic chemotherapy suggesting no age-related differences in the pharmacokinetics of filgrastim. The only consistently reported adverse event was musculoskeletal pain, which is no different from the experience in the adult population.

There is insufficient data to further evaluate filgrastim use in paediatric subjects.

e. Other special populations

Geriatric use

No overall differences in safety or effectiveness were observed between subjects over 65 years of age compared to younger adult (>18 years of age) subjects receiving cytotoxic chemotherapy and clinical experience has not identified differences in the responses between elderly and younger adult patients.

There is insufficient data to evaluate filgrastim use in geriatric subjects for other approved filgrastim indications.

Paediatric SCN patients

Cases of decreased bone density and osteoporosis have been reported in paediatric patients with SCN receiving chronic treatment with filgrastim.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

The effects of filgrastim overdosage have not been established. Discontinuation of filgrastim therapy usually results in a 50 % decrease in circulating neutrophils within 1 to 2 days, with a return to normal levels in 1 to 7 days.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Immunostimulants, colony-stimulating factors, ATC code: L03AA02

Tevagrastim is a biosimilar medicinal product. Detailed information is available on the website of the European Medicines Agency <http://www.ema.europa.eu>.

Human G-CSF is a glycoprotein which regulates the production and release of functional neutrophils from the bone marrow. Tevagrastim containing r-metHuG-CSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes. In some SCN patients, filgrastim can also induce a minor increase in the number of circulating eosinophils and basophils relative to baseline; some of these patients may present with eosinophilia or basophilia prior to treatment. Elevations of neutrophil counts are dose-dependent at recommended doses. Neutrophils produced in response to filgrastim show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function. Following termination of filgrastim therapy, circulating neutrophil counts decrease by 50 % within 1 to 2 days, and to normal levels within 1 to 7 days.

Use of filgrastim in patients undergoing cytotoxic chemotherapy leads to significant reductions in the incidence, severity and duration of neutropenia and febrile neutropenia. Treatment with filgrastim significantly reduces the duration of febrile neutropenia, antibiotic use and hospitalisation after induction chemotherapy for acute myelogenous leukaemia or myeloablative therapy followed by bone marrow transplantation. The incidence of fever and documented infections were not reduced in either setting. The duration of fever was not reduced in patients undergoing myeloablative therapy followed by bone marrow transplantation.

Use of filgrastim, either alone or after chemotherapy, mobilises haematopoietic progenitor cells into peripheral blood. These autologous PBPCs may be harvested and infused after high-dose cytotoxic therapy, either in place of or in addition to bone marrow transplantation. Infusion of PBPCs accelerates haematopoietic recovery reducing the duration of risk for haemorrhagic complications and the need for platelet transfusions.

Recipients of allogeneic PBPCs mobilised with filgrastim experienced significantly more rapid haematological recovery, leading to a significant decrease in time to unsupported platelet recovery, when compared with allogeneic bone marrow transplantation.

One retrospective European study evaluating the use of G-CSF after allogeneic bone marrow transplantation in patients with acute leukaemias suggested an increase in the risk of GvHD, treatment related mortality (TRM) and mortality when G-CSF was administered. In a separate retrospective

international study in patients with acute and chronic myelogenous leukaemias, no effect on the risk of GvHD, TRM and mortality was seen. A meta-analysis of allogeneic transplant studies, including the results of nine prospective randomised trials, 8 retrospective studies and 1 case-controlled study, did not detect an effect on the risks of acute GvHD, chronic GvHD or early treatment-related mortality.

Relative risk (95 % CI) of GvHD and TRM following treatment with G-CSF after bone marrow transplantation					
<i>Publication</i>	<i>Period of study</i>	<i>N</i>	<i>Acute grade II-IV GvHD</i>	<i>Chronic GvHD</i>	<i>TRM</i>
Meta-analysis (2003)	1986-2001 ^a	1198	1.08 (0.87, 1.33)	1.02 (0.82, 1.26)	0.70 (0.38, 1.31)
European retrospective study (2004)	1992-2002 ^b	1789	1.33 (1.08, 1.64)	1.29 (1.02, 1.61)	1.73 (1.30, 2.32)
International retrospective study (2006)	1995-2000 ^b	2110	1.11 (0.86, 1.42)	1.10 (0.86, 1.39)	1.26 (0.95, 1.67)
^a Analysis includes studies involving bone marrow transplant during this period; some studies used GM-CSF (granulocyte-macrophage colony-stimulating factor)					
^b Analysis includes patients receiving bone marrow transplant during this period					

Prior to allogeneic PBPC transplantation, use of filgrastim for the mobilisation of PBPC in normal donors allows a collection of $\geq 4 \times 10^6$ CD34⁺ cells/kg recipient body weight in the majority of the donors after two leukapheresis. Normal donors are given a dose of a 10 µg/kg/day, administered subcutaneously for 4 to 5 consecutive days.

Use of filgrastim in patients, children or adults, with SCN (severe congenital, cyclic, and idiopathic neutropenia) induces a sustained increase in absolute neutrophil counts in peripheral blood and a reduction of infection and related events.

Use of filgrastim in patients with HIV infection maintains normal neutrophil counts to allow scheduled dosing of antiviral and/or other myelosuppressive medication. There is no evidence that patients with HIV infection treated with filgrastim show an increase in HIV replication.

As with other haematopoietic growth factors, G-CSF has shown *in vitro* stimulating properties on human endothelial cells.

The efficacy and safety of Tenvagrastim has been assessed in randomised, controlled phase III studies in breast cancer, lung cancer and Non-Hodgkin-Lymphoma. There were no relevant differences between Tenvagrastim and the reference product with regard to duration of severe neutropenia and incidence of febrile neutropenia.

5.2 Pharmacokinetic properties

Randomised, single-blind, single dose, crossover studies in 196 healthy volunteers showed that the pharmacokinetic profile of Tenvagrastim was comparable to that of the reference product after subcutaneous and intravenous administration.

Clearance of filgrastim has been shown to follow first-order pharmacokinetics after both subcutaneous and intravenous administration. The serum elimination half-life of filgrastim is approximately 3.5 hours, with a clearance rate of approximately 0.6 mL/min/kg. Continuous infusion with filgrastim over a period of up to 28 days, in patients recovering from autologous bone marrow transplantation, resulted in no evidence of drug accumulation and comparable elimination half-lives. There is a positive linear correlation between the dose and the serum concentration of filgrastim, whether administered intravenously or subcutaneously. Following subcutaneous administration of recommended doses, serum concentrations were maintained above 10 ng/mL for 8 to 16 hours. The volume of distribution in blood is approximately 150 mL/kg.

In cancer patients, the pharmacokinetic profile of Tevagrastim and the reference product was comparable after single and repeated subcutaneous administration.

5.3 Preclinical safety data

Filgrastim was studied in repeated dose toxicity studies up to 1 year in duration which revealed changes attributable to the expected pharmacological actions including increases in leukocytes, myeloid hyperplasia in bone marrow, extramedullary granulopoiesis and splenic enlargement. These changes all reversed after discontinuation of treatment.

Effects of filgrastim on pre-natal development have been studied in rats and rabbits. Intravenous (80 µg/kg/day) administration of filgrastim to rabbits during the period of organogenesis was maternally toxic and increased spontaneous abortion, post-implantation loss, and decreased mean live litter size and foetal weight were observed.

Based on reported data for another filgrastim product similar to the reference product, comparable findings plus increased foetal malformations were observed at 100 µg/kg/day, a maternally toxic dose which corresponded to a systemic exposure of approximately 50-90 times the exposures observed in patients treated with the clinical dose of 5 µg/kg/day. The no observed adverse effect level for embryo-foetal toxicity in this study was 10 µg/kg/day, which corresponded to a systemic exposure of approximately 3-5 times the exposures observed in patients treated with the clinical dose.

In pregnant rats, no maternal or foetal toxicity was observed at doses up to 575 µg/kg/day. Offspring of rats administered filgrastim during the peri-natal and lactation periods, exhibited a delay in external differentiation and growth retardation (≥ 20 µg/kg/day) and slightly reduced survival rate (100 µg/kg/day).

Filgrastim had no observed effect on the fertility of male or female rats.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Acetic acid, glacial
Sodium hydroxide
Sorbitol (E420)
Polysorbate 80
Water for injections

6.2 Incompatibilities

Tevagrastim must not be diluted with sodium chloride solution.

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

Diluted filgrastim may be adsorbed to glass and plastic materials except diluted, as described in section 6.6.

6.3 Shelf life

30 months.

After dilution: Chemical and physical in-use stability of the diluted solution for infusion has been demonstrated for 24 hours at 2 °C to 8 °C. From a microbiological point of view, the product should

be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 °C to 8 °C, unless dilution has taken place in controlled and validated aseptic conditions.

6.4 Special precautions for storage

Store in a refrigerator (2 °C – 8 °C).

Within its shelf-life and for ambulatory use, the product may be removed from the refrigerator (2 °C – 8 °C) and stored at a temperature up to 25 °C for one single period of up to 4 days. If not used within 4 days, the product may be returned to the refrigerator (2 °C – 8 °C) up to the expiry date. Dispose of syringes if stored above 8 °C for more than 4 days.

For storage conditions after dilution of the medicinal product, see section 6.3.

6.5 Nature and contents of container

Pre-filled syringe (type I glass) with injection needle (stainless steel), with or without a needle safety guard.

Tevagrastim 30 MIU/0.5 mL solution for injection/infusion

Packs containing 1, 5 or 10 pre-filled syringes with 0.5 mL solution or multipacks containing 10 (2 packs of 5) pre-filled syringes with 0.5 mL solution.

Tevagrastim 48 MIU/0.8 mL solution for injection/infusion

Packs containing 1, 5 or 10 pre-filled syringes with 0.8 mL solution or multipacks containing 10 (2 packs of 5) pre-filled syringes with 0.8 mL solution.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

If required, Tevagrastim may be diluted in glucose 50 mg/mL (5 %) solution for infusion.

Dilution to a final concentration less than 0.2 MIU (2 µg) per mL is not recommended at any time.

The solution should be visually inspected prior to use. Only clear solutions without particles should be used.

For patients treated with filgrastim diluted to concentrations below 1.5 MIU (15 µg) per mL, human serum albumin (HSA) should be added to a final concentration of 2 mg/mL.

Example: In a final injection volume of 20 mL, total doses of filgrastim less than 30 MIU (300 µg) should be given with 0.2 mL of 200 mg/mL (20 %) human albumin solution added.

When diluted in glucose 50 mg/mL (5 %) solution for infusion, Tevagrastim is compatible with glass and a variety of plastics including PVC, polyolefin (a co-polymer of polypropylene and polyethylene) and polypropylene.

Tevagrastim does not contain any preservative. In view of the possible risk of microbial contamination, Tevagrastim syringes are for single use only.

Accidental exposure to freezing temperatures does not adversely affect the stability of Tevagrastim.

Using the pre-filled syringe with a needle safety guard

The needle safety guard covers the needle after injection to prevent needle stick injury. This does not affect normal operation of the syringe. Depress the plunger slowly and evenly until the entire dose has been given and the plunger cannot be depressed any further. While maintaining pressure on the plunger, remove the syringe from the patient. The needle safety guard will cover the needle when releasing the plunger.

Using the pre-filled syringe without a needle safety guard

Administer the dose as per standard protocol.

Disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

TEVA GmbH
Graf-Arco-Straße 3
89079 Ulm
Germany

8. MARKETING AUTHORISATION NUMBER(S)

Tevagrastim 30 MIU/0.5 mL solution for injection/infusion

EU/1/08/445/001

EU/1/08/445/002

EU/1/08/445/003

EU/1/08/445/004

EU/1/08/445/009

EU/1/08/445/010

EU/1/08/445/011

Tevagrastim 48 MIU/0.8 mL solution for injection/infusion

EU/1/08/445/005

EU/1/08/445/006

EU/1/08/445/007

EU/1/08/445/008

EU/1/08/445/012

EU/1/08/445/013

EU/1/08/445/014

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 15 September 2008.

Date of latest renewal: 19 July 2013.

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu/>.

ANNEX II

- A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE
SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE
FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY
AND USE**
- C. OTHER CONDITIONS AND REQUIREMENTS OF THE
MARKETING AUTHORISATION**
- D. CONDITIONS OR RESTRICTIONS WITH REGARD TO
THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT**

A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) of the biological active substance(s)

UAB Teva Baltics
Molėtų pl. 5
08409 Vilnius
Lithuania

Name and address of the manufacturer(s) responsible for batch release

Teva Pharma B.V.
Swensweg 5
2031 GA Haarlem
The Netherlands

Merckle GmbH
Graf-Arco-Straße 3
89079 Ulm
Germany

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- **Periodic safety update reports**

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- **Risk management plan (RMP)**

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGING**Outer Carton – Pre-filled Syringe****1. NAME OF THE MEDICINAL PRODUCT**

Tevagrastim 30 MIU/0.5 mL solution for injection/infusion

filgrastim

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled syringe contains 30 million international units [MIU] (300 microgram) of filgrastim in 0.5 mL (60 MIU/mL, 600 microgram/mL).

3. LIST OF EXCIPIENTS

Excipients: Sodium hydroxide, glacial acetic acid, sorbitol, polysorbate 80, water for injections. Read the package leaflet before use.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection/infusion

1 pre-filled syringe with 0.5 mL
5 pre-filled syringes with 0.5 mL
10 pre-filled syringes with 0.5 mL

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Subcutaneous use and intravenous use.

For single use only.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY**8. EXPIRY DATE**

EXP

After dilution use within 24 hours.

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

TEVA GmbH
Graf-Arco-Straße 3
89079 Ulm
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/08/445/001 1 pre-filled syringe
EU/1/08/445/002 5 pre-filled syringes
EU/1/08/445/004 10 pre-filled syringes

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Tevagrastim 30 MIU/0.5 mL

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA
--

PC
SN
NN

PARTICULARS TO APPEAR ON THE OUTER PACKAGING**Outer Carton – Pre-filled Syringe****1. NAME OF THE MEDICINAL PRODUCT**

Tevagrastim 48 MIU/0.8 mL solution for injection/infusion

filgrastim

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled syringe contains 48 million international units [MIU] (480 microgram) of filgrastim in 0.8 mL (60 MIU/mL, 600 microgram/mL).

3. LIST OF EXCIPIENTS

Excipients: Sodium hydroxide, glacial acetic acid, sorbitol, polysorbate 80, water for injections. Read the package leaflet before use.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection/infusion

1 pre-filled syringe with 0.8 mL
5 pre-filled syringes with 0.8 mL
10 pre-filled syringes with 0.8 mL

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Subcutaneous use and intravenous use.

For single use only.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY**8. EXPIRY DATE**

EXP

After dilution use within 24 hours.

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

TEVA GmbH
Graf-Arco-Straße 3
89079 Ulm
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/08/445/005 1 pre-filled syringe
EU/1/08/445/006 5 pre-filled syringes
EU/1/08/445/008 10 pre-filled syringes

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Tevagrastim 48 MIU/0.8 mL

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA
--

PC
SN
NN

PARTICULARS TO APPEAR ON THE OUTER PACKAGING**Outer Carton – Pre-filled syringe with a needle safety guard****1. NAME OF THE MEDICINAL PRODUCT**

Tevagrastim 30 MIU/0.5 mL solution for injection/infusion

filgrastim

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled syringe contains 30 million international units [MIU] (300 microgram) of filgrastim in 0.5 mL (60 MIU/mL, 600 microgram/mL).

3. LIST OF EXCIPIENTS

Excipients: Sodium hydroxide, glacial acetic acid, sorbitol, polysorbate 80, water for injections. Read the package leaflet before use.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection/infusion

1 pre-filled syringe with 0.5 mL with a needle safety guard
5 pre-filled syringes with 0.5 mL with a needle safety guard
10 pre-filled syringes with 0.5 mL with a needle safety guard

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Subcutaneous use and intravenous use.

For single use only.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY**8. EXPIRY DATE**

EXP

After dilution use within 24 hours.

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

TEVA GmbH
Graf-Arco-Straße 3
89079 Ulm
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/08/445/009 1 pre-filled syringe with a needle safety guard
EU/1/08/445/010 5 pre-filled syringe with a needle safety guard
EU/1/08/445/011 10 pre-filled syringe with a needle safety guard

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Tevagrastim 30 MIU/0.5 mL

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA
--

PC
SN
NN

PARTICULARS TO APPEAR ON THE OUTER PACKAGING**Outer Carton – Pre-filled syringe with a needle safety guard****1. NAME OF THE MEDICINAL PRODUCT**

Tevagrastim 48 MIU/0.8 mL solution for injection/infusion

filgrastim

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled syringe contains 48 million international units [MIU] (480 microgram) of filgrastim in 0.8 mL (60 MIU/mL, 600 microgram/mL).

3. LIST OF EXCIPIENTS

Excipients: Sodium hydroxide, glacial acetic acid, sorbitol, polysorbate 80, water for injections. Read the package leaflet before use.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection/infusion

1 pre-filled syringe with 0.8 mL with a needle safety guard
5 pre-filled syringes with 0.8 mL with a needle safety guard
10 pre-filled syringes with 0.8 mL with a needle safety guard

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Subcutaneous use and intravenous use.

For single use only.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY**8. EXPIRY DATE**

EXP

After dilution use within 24 hours.

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

TEVA GmbH
Graf-Arco-Straße 3
89079 Ulm
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/08/445/012 1 pre-filled syringe with a needle safety guard
EU/1/08/445/013 5 pre-filled syringe with a needle safety guard
EU/1/08/445/014 10 pre-filled syringe with a needle safety guard

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Tevagrastim 48 MIU/0.8 mL

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA
--

PC
SN
NN

PARTICULARS TO APPEAR ON THE OUTER PACKAGING**Outer Wrapper Label on Multipacks - With Blue Box****1. NAME OF THE MEDICINAL PRODUCT**

Tevagrastim 30 MIU/0.5 mL solution for injection/infusion

filgrastim

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled syringe contains 30 million international units [MIU] (300 microgram) of filgrastim in 0.5 mL (60 MIU/mL, 600 microgram/mL).

3. LIST OF EXCIPIENTS

Excipients: Sodium hydroxide, glacial acetic acid, sorbitol, polysorbate 80, water for injections. Read the package leaflet before use.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection/infusion

Multipack: 10 (2 packs of 5) pre-filled syringes containing 0.5 mL.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Subcutaneous use and intravenous use.

For single use only.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY**8. EXPIRY DATE**

EXP

After dilution use within 24 hours.

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

TEVA GmbH
Graf-Arco-Straße 3
89079 Ulm
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/08/445/003 2 x 5 pre-filled syringes

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY**15. INSTRUCTIONS ON USE****16. INFORMATION IN BRAILLE****17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN

PARTICULARS TO APPEAR ON THE OUTER PACKAGING**Outer Wrapper Label on Multipacks - With Blue Box****1. NAME OF THE MEDICINAL PRODUCT**

Tevagrastim 48 MIU/0.8 mL solution for injection/infusion

filgrastim

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled syringe contains 48 million international units [MIU] (480 microgram) of filgrastim in 0.8 mL (60 MIU/mL, 600 microgram/mL).

3. LIST OF EXCIPIENTS

Excipients: Sodium hydroxide, glacial acetic acid, sorbitol, polysorbate 80, water for injections. Read the package leaflet before use.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection/infusion

Multipack: 10 (2 packs of 5) pre-filled syringes containing 0.8 mL.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Subcutaneous use and intravenous use.

For single use only.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY**8. EXPIRY DATE**

EXP

After dilution use within 24 hours.

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

TEVA GmbH
Graf-Arco-Straße 3
89079 Ulm
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/08/445/007 2 x 5 pre-filled syringes

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY**15. INSTRUCTIONS ON USE****16. INFORMATION IN BRAILLE****17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN

PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING**Multipack Carton - Without Blue Box****1. NAME OF THE MEDICINAL PRODUCT**

Tevagrastim 30 MIU/0.5 mL solution for injection/infusion

filgrastim

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled syringe contains 30 million international units [MIU] (300 microgram) of filgrastim in 0.5 mL (60 MIU/mL, 600 microgram/mL).

3. LIST OF EXCIPIENTS

Excipients: Sodium hydroxide, glacial acetic acid, sorbitol, polysorbate 80, water for injections. Read the package leaflet before use.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection/infusion

5 pre-filled syringes containing 0.5 mL. Component of a multipack, cannot be sold separately.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Subcutaneous use and intravenous use.

For single use only.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY**8. EXPIRY DATE**

EXP

After dilution use within 24 hours.

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

TEVA GmbH
Graf-Arco-Straße 3
89079 Ulm
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/08/445/003 2 x 5 pre-filled syringes

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY**15. INSTRUCTIONS ON USE****16. INFORMATION IN BRAILLE**

Tevagrastim 30 MIU/0.5 mL

17. UNIQUE IDENTIFIER – 2D BARCODE**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING**Multipack Carton - Without Blue Box****1. NAME OF THE MEDICINAL PRODUCT**

Tevagrastim 48 MIU/0.8 mL solution for injection/infusion

filgrastim

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled syringe contains 48 million international units [MIU] (480 microgram) of filgrastim in 0.8 mL (60 MIU/mL, 600 microgram/mL).

3. LIST OF EXCIPIENTS

Excipients: Sodium hydroxide, glacial acetic acid, sorbitol, polysorbate 80, water for injections. Read the package leaflet before use.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection/infusion

5 pre-filled syringes containing 0.8 mL. Component of a multipack, cannot be sold separately.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Subcutaneous use and intravenous use.

For single use only.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY**8. EXPIRY DATE**

EXP

After dilution use within 24 hours.

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

TEVA GmbH
Graf-Arco-Straße 3
89079 Ulm
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/08/445/007 2 x 5 pre-filled syringes

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY**15. INSTRUCTIONS ON USE****16. INFORMATION IN BRAILLE**

Tevagrastim 48 MIU/0.8 mL

17. UNIQUE IDENTIFIER – 2D BARCODE**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Pre-filled syringe

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION
--

Tevagrastim 30 MIU/0.5 mL solution for injection/infusion

filgrastim

SC

IV

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT
--

0.5 mL

6. OTHER

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Pre-filled syringe

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION
--

Tevagrastim 48 MIU/0.8 mL solution for injection/infusion

filgrastim

SC

IV

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT
--

0.8 mL

6. OTHER

B. PACKAGE LEAFLET

Package leaflet: Information for the user

Tevagrastim 30 MIU/0.5 mL solution for injection/infusion Tevagrastim 48 MIU/0.8 mL solution for injection/ infusion

filgrastim

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Tevagrastim is and what it is used for
2. What you need to know before you use Tevagrastim
3. How to use Tevagrastim
4. Possible side effects
5. How to store Tevagrastim
6. Contents of the pack and other information
7. Information for injecting yourself
8. The following information is intended for healthcare professionals only

1. What Tevagrastim is and what it is used for

What Tevagrastim is

Tevagrastim is a white blood cell growth factor (granulocyte colony-stimulating factor) and belong to a group of medicines called cytokines. Growth factors are proteins that are produced naturally in the body but they can also be made using biotechnology for use as a medicine. Tevagrastim works by encouraging the bone marrow to produce more white blood cells.

What Tevagrastim is used for

A reduction in the number of white blood cells (neutropenia) can occur for several reasons and makes your body less able to fight infection. Tevagrastim stimulates the bone marrow to produce new white cells quickly.

Tevagrastim can be used

- to increase the number of white blood cells after treatment with chemotherapy to help prevent infections.
- to increase the number of white blood cells after a bone marrow transplant to help prevent infections.
- before high-dose chemotherapy to make the bone marrow produce more stem cells which can be collected and given back to you after your treatment. These can be taken from you or from a donor. The stem cells will then go back into the bone marrow and produce blood cells.
- to increase the number of white blood cells if you suffer from severe chronic neutropenia to help prevent infections.
- in patients with advanced HIV infection which will help reduce the risk of infections.

2. What you need to know before you use Tevagrastim

Do not use Tevagrastim

- if you are allergic to filgrastim or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor, pharmacist or nurse before using Tevagrastim.

Please tell your doctor before starting treatment, **if you have**

- sickle cell anaemia, as this medicine may cause sickle cell crisis
- osteoporosis (bone disease).

Talk to your doctor immediately during treatment with Tevagrastim, **if you:**

- have sudden signs of allergy such as rash, itching or hives on the skin, swelling of the face, lips, tongue or other parts of the body, shortness of breath, wheezing or trouble breathing as these could be signs of a severe allergic reaction (hypersensitivity).
- experience puffiness in your face or ankles, blood in your urine or brown-coloured urine or you notice you urinate less than usual (glomerulonephritis).
- get left upper belly (abdominal) pain, pain below the left rib cage or at the tip of your left shoulder (these may be symptoms of an enlarged spleen (splenomegaly), or possibly rupture of the spleen).
- notice unusual bleeding or bruising (these may be symptoms of a decrease in blood platelets (thrombocytopenia), with a reduced ability of your blood to clot).
- have symptoms of inflammation of aorta (the large blood vessel which transports blood from the heart to the body), this has been reported rarely in cancer patients and healthy donors. The symptoms can include fever, abdominal pain, malaise, back pain and increased inflammatory markers. Tell your doctor if you experience those symptoms.

Loss of response to filgrastim

If you experience a loss of response or failure to maintain a response with filgrastim treatment, your doctor will investigate the reasons why including whether you have developed antibodies which neutralise filgrastim's activity.

Your doctor may want to monitor you closely, see section 4 of the package leaflet.

If you are a patient with severe chronic neutropenia, you may be at risk of developing cancer of the blood (leukaemia, myelodysplastic syndrome [MDS]). You should talk to your doctor about your risks of developing cancers of the blood and what testing should be done. If you develop or are likely to develop cancers of the blood, you should not use Tevagrastim, unless instructed by your doctor.

If you are a stem cell donor, you must be aged between 16 and 60 years.

Take special care with other products that stimulate white blood cells

Tevagrastim is one of a group of products that stimulate the production of white blood cells. Your healthcare professional should always record the exact product you are using.

Other medicines and Tevagrastim

Tell your doctor or pharmacist if you are using have recently used or might use any other medicines.

Pregnancy and breast-feeding

Tevagrastim has not been tested in pregnant or breast-feeding women.

Tevagrastim is not recommended during pregnancy.

It is important to tell your doctor if you:

- are pregnant or breast-feeding
- think you may be pregnant
- are planning to have a baby

If you become pregnant during Tevagrastim treatment, please inform your doctor.

Unless your doctor directs you otherwise, you must stop breast-feeding if you use Tevagrastim.

Driving and using machines

Tevagrastim may have a minor influence on your ability to drive and use machines. This medicine may cause dizziness. It is advisable to wait and see how you feel after using this medicine and before driving or operating machinery.

Tevagrastim contains sorbitol

This medicine contains 50 mg sorbitol in each mL.

For intravenous use

Sorbitol is a source of fructose. If you (or your child) have hereditary fructose intolerance (HFI), a rare genetic disorder, you (or your child) must not receive this medicine. Patients with HFI cannot break down fructose, which may cause serious side effects. You must tell your doctor before receiving this medicine if you (or your child) have HFI or if your child can no longer take sweet foods or drinks because they feel sick, vomit or get unpleasant effects such as bloating, stomach cramps or diarrhoea.

Tevagrastim contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per pre-filled syringe, i.e. essentially 'sodium-free'.

3. How to use Tevagrastim

Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

How is Tevagrastim given and much should I take?

Tevagrastim is usually given as a daily injection into the tissue just under the skin (known as a subcutaneous injection). It can also be given as a daily slow injection into the vein (known as an intravenous infusion). The usual dose varies depending on your illness and weight. Your doctor will tell you how much Tevagrastim you should take.

Patients having a bone marrow transplant after chemotherapy:

You will normally receive your first dose of Tevagrastim at least 24 hours after your chemotherapy and at least 24 hours after receiving your bone marrow transplant.

You, or people caring for you, can be taught how to give subcutaneous injections so that you can continue your treatment at home. However, you should not attempt this unless you have been properly trained first by your health care provider.

How long will I have to take Tevagrastim?

You will need to take Tevagrastim until your white blood cell count is normal. Regular blood tests will be taken to monitor the number of white blood cells in your body. Your doctor will tell you how long you will need to take Tevagrastim.

Use in children

Tevagrastim is used to treat children who are receiving chemotherapy or who suffer from severe low white blood cell count (neutropenia). The dosing in children receiving chemotherapy is the same as for adults.

If you use more Tevagrastim than you should

Do not increase the dose your doctor has given you. If you use more Tevagrastim than you should, contact your doctor or pharmacist as soon as possible.

If you forget to use Tevagrastim

If you have missed an injection, or injected too little, contact your doctor as soon as possible. Do not take a double dose to make up for any missed doses.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Important side effects

It is important to contact your doctor immediately

- if you experience an allergic reaction including weakness, drop in blood pressure, difficulty breathing, swelling of the face (anaphylaxis), skin rash, itchy rash (urticaria), swelling of the face lips, mouth, tongue or throat (angioedema) and shortness of breath (dyspnoea).
- if you experience a cough, fever and difficulty breathing (dyspnoea) as this can be a sign of Acute Respiratory Distress Syndrome (ARDS).
- if you experience kidney injury (glomerulonephritis). Kidney injury has been seen in patients who received filgrastim. Call your doctor right away if you experience puffiness in your face or ankles, blood in your urine or brown-coloured urine or you notice you urinate less than usual.
- if you have any of the following or combination of the following side effects:
 - swelling or puffiness, which may be associated with passing water less frequently, difficulty breathing, abdominal swelling and feeling of fullness, and a general feeling of tiredness. These symptoms generally develop in a rapid fashion.These could be symptoms of condition called “capillary leak syndrome”, which causes blood to leak from the small blood vessels into your body and needs urgent medical attention.
- if you have a combination of any of the following symptoms:
 - fever, or shivering, or feeling very cold, high heart rate, confusion or disorientation, shortness of breath, extreme pain or discomfort and clammy or sweaty skin.These could be symptoms of a condition called “sepsis” (also called "blood poisoning"), a severe infection with whole-body inflammatory response which can be life-threatening and needs urgent medical attention.
- if you get left upper belly (abdominal) pain, pain below the left rib cage or pain at the tip of your shoulder, as there may be a problem with your spleen (enlargement of the spleen (splenomegaly) or rupture of the spleen).
- if you are being treated for severe chronic neutropenia and you have blood in your urine (haematuria). Your doctor may regularly test your urine if you experience this side effect or if protein is found in your urine (proteinuria).

A common side effect of Tevagrastim use is pain in your muscles or bones (musculoskeletal pain), which could be relieved by taking standard pain relief medicines (analgesics). In patients undergoing a stem cell or bone marrow transplant, Graft versus host disease (GvHD) may occur- this is a reaction of the donor cells against the patient receiving the transplant; signs and symptoms include rash on the palms of your hands or soles of your feet and ulcer and sores in your mouth, gut, liver, skin, or your eyes, lungs, vagina and joints.

In normal stem cell donors an increase in white blood cells (leukocytosis) and a decrease of platelets may be seen this reduces the ability of your blood to clot (thrombocytopenia), these will be monitored by your doctor.

You may experience the following side effects:

Very common (may affect more than 1 in 10 people):

- decrease of platelets which reduces the ability of blood to clot (thrombocytopenia)
- low red blood cell count (anaemia)

- headache
- diarrhoea
- vomiting
- nausea
- unusual hair loss or thinning (alopecia)
- tiredness (fatigue)
- soreness and swelling of the digestive tract lining which runs from the mouth to the anus (mucosal inflammation)
- fever (pyrexia)

Common (may affect up to 1 in 10 people):

- inflammation of the lung (bronchitis)
- upper respiratory tract infection
- urinary tract infection
- decreased appetite
- trouble sleeping (insomnia)
- dizziness
- decreased feeling of sensitivity, especially in the skin (hypoesthesia)
- tingling or numbness of the hands or feet (paraesthesia)
- low blood pressure (hypotension)
- high blood pressure (hypertension)
- cough
- coughing up blood (haemoptysis)
- pain in your mouth and throat (oropharyngeal pain)
- nose bleeds (epistaxis)
- constipation
- oral pain
- enlargement of the liver (hepatomegaly)
- rash
- redness of the skin (erythema)
- muscle spasm
- pain when passing urine (dysuria)
- chest pain
- pain
- generalised weakness (asthenia)
- generally feeling unwell (malaise)
- swelling in the hands and feet (oedema peripheral)
- increase of certain enzymes in the blood
- changes in blood chemistry
- transfusion reaction

Uncommon (may affect up to 1 in 100 people):

- increase in white blood cells (leukocytosis)
- allergic reaction (hypersensitivity)
- rejection of transplanted bone marrow (graft versus host disease)
- high uric acid levels in the blood, which may cause gout (hyperuricaemia) (blood uric acid increased)
- liver damage caused by blocking of the small veins within the liver (veno-occlusive disease)
- lungs do not function as they should, causing breathlessness (respiratory failure)
- swelling and/or fluid in the lungs (pulmonary oedema)
- inflammation of the lungs (interstitial lung disease)
- abnormal x-rays of the lungs (lung infiltration)
- bleeding from the lung (pulmonary haemorrhage)
- lack of absorption of oxygen in the lung (hypoxia)

- bumpy skin rash (rash maculo-papular)
- disease which causes bones to become less dense, making them weaker, more brittle and likely to break (osteoporosis)
- injection site reaction

Rare (may affect up to 1 in 1,000 people):

- severe pain in the bones, chest, gut or joints (sickle cell anaemia with crisis)
- sudden life-threatening allergic reaction (anaphylactic reaction)
- pain and swelling of the joints, similar to gout (pseudogout)
- a change in how your body regulates fluids within your body and may result in puffiness (fluid volume disturbances)
- inflammation of the blood vessels in the skin (cutaneous vasculitis)
- plum-coloured, raised, painful sores on the limbs and sometimes the face and neck with a fever (Sweets syndrome)
- worsening of rheumatoid arthritis
- unusual change in the urine
- bone density decreased
- inflammation of aorta (the large blood vessel which transports blood from the heart to the body), see section 2

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via [the national reporting system listed in Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Tevagrastim

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the outer carton and on the pre-filled syringe after EXP. The expiry date refers to the last day of that month.

Store in a refrigerator (2 °C – 8 °C).

Within its shelf-life and for ambulatory use, the product may be removed from the refrigerator (2 °C – 8 °C) and stored at a temperature up to 25 °C for one single period of up to 4 days. If not used within 4 days, the product may be returned to the refrigerator (2 °C – 8 °C) up to the expiry date. Dispose of syringes if stored above 8 °C for more than 4 days.

Do not use this medicine if you notice it is cloudy or there are particles in it.

Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

6. Contents of the pack and other information

What Tevagrastim contains

- The active substance is filgrastim. Each mL of solution for injection/infusion contains 60 million international units [MIU] (600 microgram) of filgrastim.
Tevagrastim 30 MIU/0.5 mL: Each pre-filled syringe contains 30 million international units [MIU] (300 microgram) of filgrastim in 0.5 mL solution.
Tevagrastim 48 MIU/0.8 mL: Each pre-filled syringe contains 48 million international units [MIU] (480 microgram) of filgrastim in 0.8 mL solution.

- The other ingredients are: Sodium hydroxide, glacial acetic acid, sorbitol, polysorbate 80, water for injections.

What Tevagrastim looks like and contents of the pack

Tevagrastim is a solution for injection/infusion in a pre-filled syringe. Tevagrastim is a clear and colourless solution. Each pre-filled syringe contains either 0.5 mL or 0.8 mL of solution.

Tevagrastim is supplied in packs of 1, 5 or 10 pre-filled syringes or multipacks of 10 (2 packs of 5) pre-filled syringes with injection needle and with or without a needle safety guard. Not all pack sizes may be marketed.

Marketing Authorisation Holder

TEVA GmbH
Graf-Arco-Straße 3
89079 Ulm
Germany

Manufacturer

Teva Pharma B.V.
Swensweg 5
2031 GA Haarlem
The Netherlands

Merckle GmbH
Graf-Arco-Straße 3
89079 Ulm
Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien

Teva Pharma Belgium N.V./S.A./AG
Tél/Tel: +32 38207373

Lietuva

UAB Teva Baltics
Tel: +370 52660203

България

Тева Фарма ЕАД
Тел: +359 24899585

Luxembourg/Luxemburg

Teva Pharma Belgium N.V./S.A./AG
Belgique/Belgien
Tél/Tel: +32 38207373

Česká republika

Teva Pharmaceuticals CR, s.r.o.
Tel: +420 251007111

Magyarország

Teva Gyógyszergyár Zrt.
Tel: +36 12886400

Danmark

Teva Denmark A/S
Tlf: +45 44985511

Malta

Teva Pharmaceuticals Ireland
L-Irlanda
Tel: +44 2075407117

Deutschland

TEVA GmbH
Tel: +49 73140208

Nederland

Teva Nederland B.V.
Tel: +31 8000228400

Eesti

UAB Teva Baltics Eesti filiaal
Tel: +372 6610801

Norge

Teva Norway AS
Tlf: +47 66775590

Ελλάδα

TEVA HELLAS A.E.
Τηλ: +30 2118805000

España

Teva Pharma, S.L.U.
Tel: +34 913873280

France

Teva Santé
Tél: +33 155917800

Hrvatska

Pliva Hrvatska d.o.o.
Tel: +385 13720000

Ireland

Teva Pharmaceuticals Ireland
Tel: +44 2075407117

Ísland

Teva Pharma Iceland ehf.
Sími: +354 5503300

Italia

Teva Italia S.r.l.
Tel: +39 028917981

Κύπρος

TEVA HELLAS A.E.
Ελλάδα
Τηλ: +30 2118805000

Latvija

UAB Teva Baltics filiāle Latvijā
Tel: +371 67323666

Österreich

ratiopharm Arzneimittel Vertriebs-GmbH
Tel: +43 1970070

Polska

Teva Pharmaceuticals Polska Sp. z o.o.
Tel: +48 223459300

Portugal

Teva Pharma - Produtos Farmacêuticos, Lda.
Tel: +351 214767550

România

Teva Pharmaceuticals S.R.L.
Tel: +40 212306524

Slovenija

Pliva Ljubljana d.o.o.
Tel: +386 15890390

Slovenská republika

TEVA Pharmaceuticals Slovakia s.r.o.
Tel: +421 257267911

Suomi/Finland

Teva Finland Oy
Puh/Tel: +358 201805900

Sverige

Teva Sweden AB
Tel: +46 42121100

United Kingdom (Northern Ireland)

Teva Pharmaceuticals Ireland
Ireland
Tel: +44 2075407117

This leaflet was last revised in .

Detailed information on this medicine is available on the European Medicines Agency web site:
<http://www.ema.europa.eu>.

7. Information for injecting yourself

This section contains information on how to give yourself an injection of Tevagrastim. It is important that you do not try to give yourself the injection unless you have received special training from your doctor or nurse. If you are not sure about giving yourself the injection or you have any questions, please ask your doctor or nurse for help.

It is important that you dispose of used syringes in a puncture-proof container.

How do I inject Tevagrastim myself?

You will need to give yourself the injection into the tissue just under the skin. This is known as a subcutaneous injection. You will need to have your injections at about the same time every day.

Equipment that you need

To give yourself a subcutaneous injection you will need:

- a pre-filled syringe of Tevagrastim;
- alcohol wipes or similar;
- a puncture-proof container (plastic container provided by the hospital or pharmacy) so you can dispose of used syringes safely.


What should I do before I give myself a subcutaneous injection of Tevagrastim?

1. Try to self-inject at approximately the same time every day.
2. Take your Tevagrastim pre-filled syringe out of the refrigerator.
3. Check the expiry date on the pre-filled syringe label (EXP). Do not use it if the date has passed the last day of the month shown.
4. Check the appearance of Tevagrastim. It must be a clear and colourless liquid. If there are particles in it, you must not use it.
5. For a more comfortable injection, let the pre-filled syringe stand for 30 minutes to reach room temperature or hold the pre-filled syringe gently in your hand for a few minutes. Do not warm Tevagrastim in any other way (for example, do **not** warm it in a microwave or in hot water).
6. Do **not** remove the cover from the syringe until you are ready to inject.
7. **Wash your hands thoroughly.**
8. Find a comfortable, well-lit place and put everything you need where you can reach them (the Tevagrastim pre-filled syringe, alcohol wipes and the puncture-proof container).

How do I prepare my Tevagrastim injection?

Before you inject Tevagrastim you must do the following:

1. Hold the syringe and gently take the cover from the needle without twisting. Pull straight as shown in pictures 1 and 2. Do not touch the needle or push the plunger.




2. You may notice a small air bubble in the pre-filled syringe. If there are air bubbles present, gently tap the syringe with your fingers until the air bubbles rise to the top of the syringe. With the syringe pointing upwards, expel all air from the syringe by pushing the plunger upwards.
3. The syringe has a scale on the syringe barrel. Push the plunger up to the number (mL) on the syringe that matches the dose of Tevagrastim that your doctor prescribed.
4. Check again to make sure the correct dose of Tevagrastim is in the syringe.
5. You can now use the pre-filled syringe.


Where should I give my injection?

The most suitable places to inject yourself are:

- the top of your thighs; and
- the abdomen, except for the area around the navel (see picture 3).



3




4

If someone else is injecting you, they can also use the back of your arms (see picture 4).


It is better to change the injection site every day to avoid the risk of soreness at any one site.

How do I give my injection?

1. Disinfect the injection site by using an alcohol wipe and pinch the skin between your thumb and forefinger, without squeezing it (see picture 5).
2. Put the needle fully into the skin as shown by your nurse or doctor (see picture 6).
3. Pull slightly on the plunger to check that a blood vessel has not been punctured. If you see blood in the syringe, remove the needle and re-insert it in another place.
4. Inject the liquid slowly and evenly, always keeping your skin pinched.
5. Inject only the dose your doctor has told you.
6. After injecting the liquid, remove the needle and let go of your skin.
7. Only use each syringe for one injection. Do not use any Tevagrastim that is left in the syringe.



5



6

Remember

If you have any problems, please do not be afraid to ask your doctor or nurse for help and advice.

Disposing of used syringes

- Do not put the cover back on used needles.
- Put used syringes into the puncture-proof container and keep this container out of the sight and reach of children.
- Dispose of the full puncture-proof container as instructed by your doctor, nurse or pharmacist.
- Never put the syringes that you have used into your normal household rubbish bin.

8. The following information is intended for healthcare professionals only

Tevagrastim does not contain any preservative. In view of the possible risk of microbial contamination, Tevagrastim syringes are for single use only.

Accidental exposure to freezing temperatures does not adversely affect the stability of Tevagrastim.

Tevagrastim should not be diluted with sodium chloride solution. This medicinal product must not be mixed with other medicinal products except those mentioned below. Diluted filgrastim may be adsorbed to glass and plastic materials except diluted, as mentioned below.

If required, Tevagrastim may be diluted in glucose 50 mg/mL (5 %) solution for infusion. Dilution to a final concentration less than 0.2 MIU (2 µg) per mL is not recommended at any time. The solution should be visually inspected prior to use. Only clear solutions without particles should be used. For patients treated with filgrastim diluted to concentrations below 1.5 MIU (15 µg) per mL, human serum albumin (HSA) should be added to a final concentration of 2 mg/mL. Example: In a final injection volume of 20 mL, total doses of filgrastim less than 30 MIU (300 µg) should be given with 0.2 mL of 200 mg/mL (20 %) human albumin solution added. When diluted in glucose 50 mg/mL (5 %) solution for infusion, Tevagrastim is compatible with glass and a variety of plastics including PVC, polyolefin (a co-polymer of polypropylene and polyethylene) and polypropylene.

After dilution: Chemical and physical in-use stability of the diluted solution for infusion has been demonstrated for 24 hours at 2 °C to 8 °C. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 °C to 8 °C, unless dilution has taken place in controlled and validated aseptic conditions.

Using the pre-filled syringe without a needle safety guard

Administer the dose as per standard protocol.

Disposal

Any unused product or waste material should be disposed of in accordance with local requirements.

Package leaflet: Information for the user

Tevagrastim 30 MIU/0.5 mL solution for injection/infusion

Tevagrastim 48 MIU/0.8 mL solution for injection/infusion

filgrastim

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Tevagrastim is and what it is used for
2. What you need to know before you use Tevagrastim
3. How to use Tevagrastim
4. Possible side effects
5. How to store Tevagrastim
6. Contents of the pack and other information
7. Information for injecting yourself
8. The following information is intended for healthcare professionals only

1. What Tevagrastim is and what it is used for

What Tevagrastim is

Tevagrastim is a white blood cell growth factor (granulocyte colony-stimulating factor) and belong to a group of medicines called cytokines. Growth factors are proteins that are produced naturally in the body but they can also be made using biotechnology for use as a medicine. Tevagrastim works by encouraging the bone marrow to produce more white blood cells.

What Tevagrastim is used for

A reduction in the number of white blood cells (neutropenia) can occur for several reasons and makes your body less able to fight infection. Tevagrastim stimulates the bone marrow to produce new white cells quickly.

Tevagrastim can be used

- to increase the number of white blood cells after treatment with chemotherapy to help prevent infections.
- to increase the number of white blood cells after a bone marrow transplant to help prevent infections.
- before high-dose chemotherapy to make the bone marrow produce more stem cells which can be collected and given back to you after your treatment. These can be taken from you or from a donor. The stem cells will then go back into the bone marrow and produce blood cells.
- to increase the number of white blood cells if you suffer from severe chronic neutropenia to help prevent infections.
- in patients with advanced HIV infection which will help reduce the risk of infections.

2. What you need to know before you use Tevagrastim

Do not use Tevagrastim

- if you are allergic to filgrastim or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor, pharmacist or nurse before using Tevagrastim

Please tell your doctor before starting treatment, **if you have**

- sickle cell anaemia, as this medicine may cause sickle cell crisis
- osteoporosis (bone disease).

Talk to your doctor immediately during treatment with Tevagrastim **if you:**

- have sudden signs of allergy such as rash, itching or hives on the skin, swelling of the face, lips, tongue or other parts of the body, shortness of breath, wheezing or trouble breathing as these could be signs of a severe allergic reaction (hypersensitivity).
- experience puffiness in your face or ankles, blood in your urine or brown-coloured urine or you notice you urinate less than usual (glomerulonephritis).
- get left upper belly (abdominal) pain, pain below the left rib cage or at the tip of your left shoulder (these may be symptoms of an enlarged spleen (splenomegaly), or possibly rupture of the spleen).
- notice unusual bleeding or bruising (these may be symptoms of a decrease in blood platelets (thrombocytopenia), with a reduced ability of your blood to clot).
- have symptoms of inflammation of aorta (the large blood vessel which transports blood from the heart to the body), this has been reported rarely in cancer patients and healthy donors. The symptoms can include fever, abdominal pain, malaise, back pain and increased inflammatory markers. Tell your doctor if you experience those symptoms.

Loss of response to filgrastim

If you experience a loss of response or failure to maintain a response with filgrastim treatment, your doctor will investigate the reasons why including whether you have developed antibodies which neutralise filgrastim's activity.

Your doctor may want to monitor you closely, see section 4 of the package leaflet.

If you are a patient with severe chronic neutropenia, you may be at risk of developing cancer of the blood (leukaemia, myelodysplastic syndrome [MDS]). You should talk to your doctor about your risks of developing cancers of the blood and what testing should be done. If you develop or are likely to develop cancers of the blood, you should not use Tevagrastim, unless instructed by your doctor.

If you are a stem cell donor, you must be aged between 16 and 60 years.

Take special care with other products that stimulate white blood cells

Tevagrastim is one of a group of products that stimulate the production of white blood cells. Your healthcare professional should always record the exact product you are using.

Other medicines and Tevagrastim

Tell your doctor or pharmacist if you are using have recently used or might use any other medicines.

Pregnancy and breast-feeding

Tevagrastim has not been tested in pregnant or breast-feeding women.

Tevagrastim is not recommended during pregnancy.

It is important to tell your doctor if you:

- are pregnant or breast-feeding,

- think you may be pregnant or
- are planning to have a baby

If you become pregnant during Tevagrastim treatment, please inform your doctor.

Unless your doctor directs you otherwise, you must stop breast-feeding if you use Tevagrastim.

Driving and using machines

Tevagrastim may have a minor influence on your ability to drive and use machines. This medicine may cause dizziness. It is advisable to wait and see how you feel after using this medicine and before driving or operating machinery.

Tevagrastim contains sorbitol

This medicine contains 50 mg sorbitol in each mL.

For intravenous use

Sorbitol is a source of fructose. If you (or your child) have hereditary fructose intolerance (HFI), a rare genetic disorder, you (or your child) must not receive this medicine. Patients with HFI cannot break down fructose, which may cause serious side effects. You must tell your doctor before receiving this medicine if you (or your child) have HFI or if your child can no longer take sweet foods or drinks because they feel sick, vomit or get unpleasant effects such as bloating, stomach cramps or diarrhoea.

Tevagrastim contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per pre-filled syringe, i.e. essentially 'sodium-free'.

3. How to use Tevagrastim

Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

How is Tevagrastim given and much should I take?

Tevagrastim is usually given as a daily injection into the tissue just under the skin (known as a subcutaneous injection). It can also be given as a daily slow injection into the vein (known as an intravenous infusion). The usual dose varies depending on your illness and weight. Your doctor will tell you how much Tevagrastim you should take.

Patients having a bone marrow transplant after chemotherapy:

You will normally receive your first dose of Tevagrastim at least 24 hours after your chemotherapy and at least 24 hours after receiving your bone marrow transplant.

You, or people caring for you, can be taught how to give subcutaneous injections so that you can continue your treatment at home. However, you should not attempt this unless you have been properly trained first by your health care provider.

How long will I have to take Tevagrastim?

You will need to take Tevagrastim until your white blood cell count is normal. Regular blood tests will be taken to monitor the number of white blood cells in your body. Your doctor will tell you how long you will need to take Tevagrastim.

Use in children

Tevagrastim is used to treat children who are receiving chemotherapy or who suffer from severe low white blood cell count (neutropenia). The dosing in children receiving chemotherapy is the same as for adults.

If you use more Tevagrastim than you should

Do not increase the dose your doctor has given you. If you use more Tevagrastim than you should, contact your doctor or pharmacist as soon as possible.

If you forget to use Tevagrastim

If you have missed an injection, or injected too little, contact your doctor as soon as possible. Do not take a double dose to make up for any missed doses.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Important side effects

It is important to contact your doctor immediately

- if you experience an allergic reaction including weakness, drop in blood pressure, difficulty breathing, swelling of the face (anaphylaxis), skin rash, itchy rash (urticaria), swelling of the face lips, mouth, tongue or throat (angioedema) and shortness of breath (dyspnoea).
- if you experience a cough, fever and difficulty breathing (dyspnoea) as this can be a sign of Acute Respiratory Distress Syndrome (ARDS).
- if you experience kidney injury (glomerulonephritis). Kidney injury has been seen in patients who received filgrastim. Call your doctor right away if you experience puffiness in your face or ankles, blood in your urine or brown-coloured urine or you notice you urinate less than usual.
- if you have any of the following or combination of the following side effects:
 - swelling or puffiness, which may be associated with passing water less frequently, difficulty breathing, abdominal swelling and feeling of fullness, and a general feeling of tiredness. These symptoms generally develop in a rapid fashion.
These could be symptoms of condition called “capillary leak syndrome”, which causes blood to leak from the small blood vessels into your body and needs urgent medical attention.
- if you have a combination of any of the following symptoms:
 - fever, or shivering, or feeling very cold, high heart rate, confusion or disorientation, shortness of breath, extreme pain or discomfort and clammy or sweaty skin.
These could be symptoms of a condition called “sepsis” (also called "blood poisoning"), a severe infection with whole-body inflammatory response which can be life-threatening and needs urgent medical attention.
- if you get left upper belly (abdominal) pain, pain below the left rib cage or pain at the tip of your shoulder, as there may be a problem with your spleen (enlargement of the spleen (splenomegaly) or rupture of the spleen).
- if you are being treated for severe chronic neutropenia and you have blood in your urine (haematuria). Your doctor may regularly test your urine if you experience this side effect or if protein is found in your urine (proteinuria).

A common side effect of Tevagrastim use is pain in your muscles or bones (musculoskeletal pain), which could be relieved by taking standard pain relief medicines (analgesics). In patients undergoing a stem cell or bone marrow transplant, Graft versus host disease (GvHD) may occur- this is a reaction of the donor cells against the patient receiving the transplant; signs and symptoms include rash on the palms of your hands or soles of your feet and ulcer and sores in your mouth, gut, liver, skin, or your eyes, lungs, vagina and joints.

In normal stem cell donors an increase in white blood cells (leukocytosis) and a decrease of platelets may be seen this reduces the ability of your blood to clot (thrombocytopenia), these will be monitored by your doctor.

You may experience the following side effects:

Very common (may affect more than 1 in 10 people):

- decrease of platelets which reduces the ability of blood to clot (thrombocytopenia)
- low red blood cell count (anaemia)
- headache
- diarrhoea
- vomiting
- nausea
- unusual hair loss or thinning (alopecia)
- tiredness (fatigue)
- soreness and swelling of the digestive tract lining which runs from the mouth to the anus (mucosal inflammation)
- fever (pyrexia)

Common (may affect up to 1 in 10 people):

- inflammation of the lung (bronchitis)
- upper respiratory tract infection
- urinary tract infection
- decreased appetite
- trouble sleeping (insomnia)
- dizziness
- decreased feeling of sensitivity, especially in the skin (hypoesthesia)
- tingling or numbness of the hands or feet (paraesthesia)
- low blood pressure (hypotension)
- high blood pressure (hypertension)
- cough
- coughing up blood (haemoptysis)
- pain in your mouth and throat (oropharyngeal pain)
- nose bleeds (epistaxis)
- constipation
- oral pain
- enlargement of the liver (hepatomegaly)
- rash
- redness of the skin (erythema)
- muscle spasm
- pain when passing urine (dysuria)
- chest pain
- pain
- generalised weakness (asthenia)
- generally feeling unwell (malaise)
- swelling in the hands and feet (oedema peripheral)
- increase of certain enzymes in the blood
- changes in blood chemistry
- transfusion reaction

Uncommon (may affect up to 1 in 100 people):

- increase in white blood cells (leukocytosis)
- allergic reaction (hypersensitivity)
- rejection of transplanted bone marrow (graft versus host disease)
- high uric acid levels in the blood, which may cause gout (hyperuricaemia) (blood uric acid increased)
- liver damage caused by blocking of the small veins within the liver (veno-occlusive disease)
- lungs do not function as they should, causing breathlessness (respiratory failure)
- swelling and/or fluid in the lungs (pulmonary oedema)
- inflammation of the lungs (interstitial lung disease)

- abnormal x-rays of the lungs (lung infiltration)
- bleeding from the lung (pulmonary haemorrhage)
- lack of absorption of oxygen in the lung (hypoxia)
- bumpy skin rash (rash maculo-papular)
- disease which causes bones to become less dense, making them weaker, more brittle and likely to break (osteoporosis)
- injection site reaction

Rare (may affect up to 1 in 1,000 people):

- severe pain in the bones, chest, gut or joints (sickle cell anaemia with crisis)
- sudden life-threatening allergic reaction (anaphylactic reaction)
- pain and swelling of the joints, similar to gout (pseudogout)
- a change in how your body regulates fluids within your body and may result in puffiness (fluid volume disturbances)
- inflammation of the blood vessels in the skin (cutaneous vasculitis)
- plum-coloured, raised, painful sores on the limbs and sometimes the face and neck with a fever (Sweets syndrome)
- worsening of rheumatoid arthritis
- unusual change in the urine
- bone density decreased
- inflammation of aorta (the large blood vessel which transports blood from the heart to the body), see section 2

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Tevagrastim

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the outer carton and on the pre-filled syringe after EXP. The expiry date refers to the last day of that month.

Store in a refrigerator (2 °C – 8 °C).

Within its shelf-life and for ambulatory use, the product may be removed from the refrigerator (2 °C – 8 °C) and stored at a temperature up to 25 °C for one single period of up to 4 days. If not used within 4 days, the product may be returned to the refrigerator (2 °C – 8 °C) up to the expiry date. Dispose of syringes if stored above 8 °C for more than 4 days.

Do not use this medicine if you notice it is cloudy or there are particles in it.

Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

6. Contents of the pack and other information

What Tevagrastim contains

- The active substance is filgrastim. Each mL of solution for injection/infusion contains 60 million international units [MIU] (600 microgram) of filgrastim.

Tevagrastim 30 MIU/0.5 mL: Each pre-filled syringe contains 30 million international units [MIU] (300 microgram) of filgrastim in 0.5 mL solution.

Tevagrastim 48 MIU/0.8 mL: Each pre-filled syringe contains 48 million international units [MIU] (480 microgram) of filgrastim in 0.8 mL solution.

- The other ingredients are: Sodium hydroxide, glacial acetic acid, sorbitol, polysorbate 80, water for injections.

What Tevagrastim looks like and contents of the pack

Tevagrastim is a solution for injection/infusion in a pre-filled syringe. Tevagrastim is a clear and colourless solution. Each pre-filled syringe contains either 0.5 mL or 0.8 mL of solution.

Tevagrastim is supplied in packs of 1, 5 or 10 pre-filled syringes or multipacks of 10 (2 packs of 5) pre-filled syringes with injection needle and with or without a needle safety guard. Not all pack sizes may be marketed.

Marketing Authorisation Holder

TEVA GmbH
Graf-Arco-Straße 3
89079 Ulm
Germany

Manufacturer

Teva Pharma B.V.
Swensweg 5
2031 GA Haarlem
The Netherlands

Merckle GmbH
Graf-Arco-Straße 3
89079 Ulm
Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien

Teva Pharma Belgium N.V./S.A./AG
Tél/Tel: +32 38207373

Lietuva

UAB Teva Baltics
Tel: +370 52660203

България

Тева Фарма ЕАД
Тел: +359 24899585

Luxembourg/Luxemburg

Teva Pharma Belgium N.V./S.A./AG
Belgique/Belgien
Tél/Tel: +32 38207373

Česká republika

Teva Pharmaceuticals CR, s.r.o.
Tel: +420 251007111

Magyarország

Teva Gyógyszergyár Zrt.
Tel: +36 12886400

Danmark

Teva Denmark A/S
Tlf: +45 44985511

Malta

Teva Pharmaceuticals Ireland
L-Irlanda
Tel: +44 2075407117

Deutschland

TEVA GmbH
Tel: +49 73140208

Nederland

Teva Nederland B.V.
Tel: +31 8000228400

Eesti

UAB Teva Baltics Eesti filiaal
Tel: +372 6610801

Ελλάδα

TEVA HELLAS A.E.
Τηλ: +30 2118805000

España

Teva Pharma, S.L.U.
Tel: +34 913873280

France

Teva Santé
Tél: +33 155917800

Hrvatska

Pliva Hrvatska d.o.o.
Tel: +385 13720000

Ireland

Teva Pharmaceuticals Ireland
Tel: +44 2075407117

Ísland

Teva Pharma Iceland ehf.
Sími: +354 5503300

Italia

Teva Italia S.r.l.
Tel: +39 028917981

Κύπρος

TEVA HELLAS A.E.
Ελλάδα
Τηλ: +30 2118805000

Latvija

UAB Teva Baltics filiāle Latvijā
Tel: +371 67323666

Norge

Teva Norway AS
Tlf: +47 66775590

Österreich

ratiopharm Arzneimittel Vertriebs-GmbH
Tel: +43 1970070

Polska

Teva Pharmaceuticals Polska Sp. z o.o.
Tel: +48 223459300

Portugal

Teva Pharma - Produtos Farmacêuticos, Lda.
Tel: +351 214767550

România

Teva Pharmaceuticals S.R.L.
Tel: +40 212306524

Slovenija

Pliva Ljubljana d.o.o.
Tel: +386 15890390

Slovenská republika

TEVA Pharmaceuticals Slovakia s.r.o.
Tel: +421 257267911

Suomi/Finland

Teva Finland Oy
Puh/Tel: +358 201805900

Sverige

Teva Sweden AB
Tel: +46 42121100

United Kingdom (Northern Ireland)

Teva Pharmaceuticals Ireland
Ireland
Tel: +44 2075407117

This leaflet was last revised in .

Detailed information on this medicine is available on the European Medicines Agency web site:
<http://www.ema.europa.eu>.

7. Information for injecting yourself

This section contains information on how to give yourself an injection of Tevagrastim. It is important that you do not try to give yourself the injection unless you have received special training from your doctor or nurse. If you are not sure about giving yourself the injection or you have any questions, please ask your doctor or nurse for help.

How do I inject Tevagrastim myself?

You will need to give yourself the injection into the tissue just under the skin. This is known as a subcutaneous injection. You will need to have your injections at about the same time every day.

Equipment that you need

To give yourself a subcutaneous injection you will need:

- a pre-filled syringe of Tevagrastim;
- alcohol wipes or similar.


What should I do before I give myself a subcutaneous injection of Tevagrastim?

1. Try to self-inject at approximately the same time every day.
2. Take your Tevagrastim pre-filled syringe out of the refrigerator.
3. Check the expiry date on the pre-filled syringe label (EXP). Do not use it if the date has passed the last day of the month shown.
4. Check the appearance of Tevagrastim. It must be a clear and colourless liquid. If there are particles in it, you must not use it.
5. For a more comfortable injection, let the pre-filled syringe stand for 30 minutes to reach room temperature or hold the pre-filled syringe gently in your hand for a few minutes. Do not warm Tevagrastim in any other way (for example, do **not** warm it in a microwave or in hot water).
6. Do **not** remove the cover from the syringe until you are ready to inject.
7. **Wash your hands thoroughly.**
8. Find a comfortable, well-lit place and put everything you need where you can reach them (the Tevagrastim pre-filled syringe and alcohol wipes).

How do I prepare my Tevagrastim injection?

Before you inject Tevagrastim you must do the following:

1. Hold the syringe and gently take the cover from the needle without twisting. Pull straight as shown in pictures 1 and 2. Do not touch the needle or push the plunger.




2. You may notice a small air bubble in the pre-filled syringe. If there are air bubbles present, gently tap the syringe with your fingers until the air bubbles rise to the top of the syringe. With the syringe pointing upwards, expel all air from the syringe by pushing the plunger upwards.
3. The syringe has a scale on the syringe barrel. Push the plunger up to the number (mL) on the syringe that matches the dose of Tevagrastim that your doctor prescribed.
4. Check again to make sure the correct dose of Tevagrastim is in the syringe.
5. You can now use the pre-filled syringe.


Where should I give my injection?

The most suitable places to inject yourself are:

- the top of your thighs; and
- the abdomen, except for the area around the navel (see picture 3).



3




4

If someone else is injecting you, they can also use the back of your arms (see picture 4).


It is better to change the injection site every day to avoid the risk of soreness at any one site.

How do I give my injection?


1. Disinfect the injection site by using an alcohol wipe and pinch the skin between your thumb and forefinger, without squeezing it (see picture 5).
2. Put the needle fully into the skin as shown by your nurse or doctor (see picture 6).
3. Pull slightly on the plunger to check that a blood vessel has not been punctured. If you see blood in the syringe, remove the needle and re-insert it in another place.
4. Always keeping your skin pinched, depress the plunger slowly and evenly until the entire dose has been given and the plunger cannot be depressed any further. Do not release the pressure on the plunger!
5. Inject only the dose your doctor has told you.
6. After injecting the liquid, remove the needle while maintaining pressure on the plunger and then let go of your skin.
7. Let go of the plunger. The needle safety guard will rapidly move to cover the needle (see picture 7).



5



6



7

Remember

If you have any problems, please do not be afraid to ask your doctor or nurse for help and advice.

Disposing of used syringes

- The needle safety guard prevents needle stick injuries after use, so no special precautions for disposal are required. Dispose of the syringe as instructed by your doctor, nurse or pharmacist.

8. The following information is intended for healthcare professionals only

Tevagrastim does not contain any preservative. In view of the possible risk of microbial contamination, Tevagrastim syringes are for single use only.

Accidental exposure to freezing temperatures does not adversely affect the stability of Tevagrastim.

Tevagrastim should not be diluted with sodium chloride solution. This medicinal product must not be mixed with other medicinal products except those mentioned below. Diluted filgrastim may be adsorbed to glass and plastic materials except diluted, as mentioned below.

If required, Tevagrastim may be diluted in glucose 50 mg/mL (5 %) solution for infusion. Dilution to a final concentration less than 0.2 MIU (2 µg) per mL is not recommended at any time. The solution should be visually inspected prior to use. Only clear solutions without particles should be used. For patients treated with filgrastim diluted to concentrations below 1.5 MIU (15 µg) per mL, human serum albumin (HSA) should be added to a final concentration of 2 mg/mL. Example: In a final injection volume of 20 mL, total doses of filgrastim less than 30 MIU (300 µg) should be given with 0.2 mL of 200 mg/mL (20 %) human albumin solution added. When diluted in glucose 50 mg/mL (5 %) solution for infusion, Tevagrastim is compatible with glass and a variety of plastics including PVC, polyolefin (a co-polymer of polypropylene and polyethylene) and polypropylene.

After dilution: Chemical and physical in-use stability of the diluted solution for infusion has been demonstrated for 24 hours at 2 °C to 8 °C. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 °C to 8 °C, unless dilution has taken place in controlled and validated aseptic conditions.

Using the pre-filled syringe with a needle safety guard

The needle safety guard covers the needle after injection to prevent needle stick injury. This does not affect normal operation of the syringe. Depress the plunger slowly and evenly until the entire dose has been given and the plunger cannot be depressed any further. While maintaining pressure on the plunger, remove the syringe from the patient. The needle safety guard will cover the needle when releasing the plunger.

Disposal

Any unused product or waste material should be disposed of in accordance with local requirements.